Emergent BioSolutions Bilan de santé
Santé financière contrôle des critères 3/6
Emergent BioSolutions possède un total de capitaux propres de $523.1M et une dette totale de $573.6M, ce qui porte son ratio d'endettement à 109.7%. Son actif total et son passif total sont $1.3B et de $797.3M. L'EBIT de Emergent BioSolutions est $75.3M ce qui fait que son ratio de couverture des intérêts 1.4. Elle dispose de liquidités et de placements à court terme de $160.3M.
Informations clés
109.65%
Ratio d'endettement
US$573.60m
Dette
| Ratio de couverture des intérêts | 1.4x |
| Argent liquide | US$160.30m |
| Fonds propres | US$523.10m |
| Total du passif | US$797.30m |
| Total des actifs | US$1.32b |
Mises à jour récentes de la santé financière
Article d’analyse • Nov 27
Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d’analyse • Jul 05
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Mar 05
Is Emergent BioSolutions (NYSE:EBS) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Oct 28
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Recent updates
Mise à jour du récit • Apr 22
EBS: Earnings Reset And Buybacks Will Support Long Term Contract Upside
Narrative Update The consensus analyst price target for Emergent BioSolutions has been cut by $3 to $12. Analysts cite reduced earnings expectations after the recent earnings miss as the key driver of this change.Mise à jour du récit • Apr 07
EBS: Earnings Reset And Buybacks Will Support Smallpox Contract Upside Potential
Analysts have trimmed their price target for Emergent BioSolutions to $12 from $15, citing reduced earnings expectations following the recent earnings miss. Analyst Commentary Bullish Takeaways Bullish analysts are keeping a positive stance on the shares even after the earnings miss, suggesting they still see room for upside from the current price level.Mise à jour du récit • Mar 24
EBS: Earnings Reset And Buybacks Will Support Future Upside Potential
Analysts have trimmed their price target on Emergent BioSolutions to $12 from $15, citing lowered earnings expectations following the recent earnings miss. Analyst Commentary Analysts have reacted to the earnings miss by cutting their price target on Emergent BioSolutions to $12 from $15, reflecting reduced earnings expectations while still seeing room for potential upside at current levels.Mise à jour du récit • Mar 09
EBS: Reset Earnings Bar And Buybacks Will Support Future Upside
Analysts have reduced their fair value estimate for Emergent BioSolutions to $12 from $13.50, citing lower earnings expectations after the recent miss, while also updating their assumptions for revenue growth, profit margins, and future P/E levels. Analyst Commentary Bullish Takeaways Bullish analysts are still comfortable assigning a fair value of $12, which suggests they see the earnings miss as an adjustment to expectations rather than a thesis-breaking event.Article d’analyse • Dec 23
Emergent BioSolutions Inc. (NYSE:EBS) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Emergent BioSolutions Inc. ( NYSE:EBS ) shares have been powering on, with a gain of 28...Article d’analyse • Nov 27
Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Nov 07
Emergent BioSolutions: Solid Q3, Expecting Better Days To Come
Summary Emergent BioSolutions maintains a Buy rating, supported by recent Q3 earnings beat and CEO Joe Papa's turnaround progress. EBS reported Q3 revenues of $231.1M and net income of $51.2M, surpassing guidance, with improved capital allocation and reduced net debt. Narcan sales declined year-over-year due to pricing and volume pressures, but sequential growth and strong demand signal market stabilization. Cost reductions, strategic government contracts, and effective downsizing position EBS for improved performance and potential upside amid sector challenges. Read the full article on Seeking AlphaArticle d’analyse • Oct 08
Emergent BioSolutions Inc.'s (NYSE:EBS) Shares Bounce 31% But Its Business Still Trails The Industry
The Emergent BioSolutions Inc. ( NYSE:EBS ) share price has done very well over the last month, posting an excellent...Article d’analyse • Aug 24
Improved Revenues Required Before Emergent BioSolutions Inc. (NYSE:EBS) Stock's 29% Jump Looks Justified
Emergent BioSolutions Inc. ( NYSE:EBS ) shares have continued their recent momentum with a 29% gain in the last month...Article d’analyse • Aug 15
Emergent BioSolutions' (NYSE:EBS) Solid Earnings May Rest On Weak Foundations
NYSE:EBS 1 Year Share Price vs Fair Value Explore Emergent BioSolutions's Fair Values from the Community and select...Article d’analyse • Aug 10
Earnings Update: Here's Why Analysts Just Lifted Their Emergent BioSolutions Inc. (NYSE:EBS) Price Target To US$13.50
The investors in Emergent BioSolutions Inc. 's ( NYSE:EBS ) will be rubbing their hands together with glee today, after...Article d’analyse • Jul 05
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • May 11
Emergent BioSolutions Inc.'s (NYSE:EBS) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Those holding Emergent BioSolutions Inc. ( NYSE:EBS ) shares would be relieved that the share price has rebounded 29...
Nouveau récit • Apr 26
Transformational Initiatives Will Optimize Medical Countermeasures And Operations
Strategic refocus on medical countermeasures and NARCAN Nasal Spray aims to maintain market leadership and drive revenue growth.Seeking Alpha • Mar 26
Emergent BioSolutions: I See Further Downside Ahead In This Value Trap
Summary Emergent BioSolutions faces declining revenues, increasing competition, and limited growth potential, leading to a sell rating due to poor risk-reward profile. NARCAN, their main revenue generator, is experiencing pricing pressure and competition, with limited growth prospects outside North America. Management's plans for international expansion and future growth are vague and unlikely to succeed, further weakening the investment thesis. The company's financials show inconsistent revenue, declining profit margins, and reliance on asset sales, with no clear turnaround plan in sight. Read the full article on Seeking AlphaArticle d’analyse • Mar 21
Benign Growth For Emergent BioSolutions Inc. (NYSE:EBS) Underpins Stock's 31% Plummet
The Emergent BioSolutions Inc. ( NYSE:EBS ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Mar 20
Emergent BioSolutions: Attractive Biotech With Proven Business Clouded By Washington Funding Issues
Summary Emergent BioSolutions has faced significant challenges, with its stock price falling sharply since my previous article in July 2024. The company's updated mission focuses on combating health threats like smallpox, Ebola, anthrax, and opioid overdoses. I will evaluate Emergent's investment potential using Q4 2024 earnings reports, including its press release, conference call, 10-Q, and slides. This analysis aims to determine if Emergent's strategic goals align with its current financial performance and future prospects. Read the full article on Seeking AlphaArticle d’analyse • Mar 05
Is Emergent BioSolutions (NYSE:EBS) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Jan 22
There's No Escaping Emergent BioSolutions Inc.'s (NYSE:EBS) Muted Revenues Despite A 26% Share Price Rise
Emergent BioSolutions Inc. ( NYSE:EBS ) shareholders would be excited to see that the share price has had a great...Seeking Alpha • Jan 14
Emergent BioSolutions: Stock Is A Likely Winner In 2025
Summary Emergent BioSolutions has a sound turnaround strategy in place that is producing positive results. Emergent BioSolutions' cost-cutting efforts have the company on track for profitability in 2025. The undervaluation leaves plenty of room for the upside for the stock. Read the full article on Seeking AlphaArticle d’analyse • Nov 09
Emergent BioSolutions Inc. (NYSE:EBS) Shares Fly 32% But Investors Aren't Buying For Growth
Emergent BioSolutions Inc. ( NYSE:EBS ) shares have continued their recent momentum with a 32% gain in the last month...Seeking Alpha • Nov 08
Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic
Summary Emergent BioSolutions' Q3 earnings report led to a 20% surge in its share price, now valued at ~$11 per share. The company's market cap is approximately $595 million, reflecting investor confidence post-earnings announcement. Emergent focuses on innovative preparedness and response solutions for various public health threats. The significant share price increase underscores market optimism about Emergent's strategic direction and financial performance. The presence of veteran Joe Papa as CEO is a reassuring one - his ability to complete business transformations is impressive. If the CEO stays, EBS stock price is likely to keep growing. Read the full article on Seeking AlphaArticle d’analyse • Oct 28
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Oct 04
Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario
Summary Emergent BioSolutions is showing signs of a potential turnaround with strategic restructuring, cost-cutting, and securing significant contracts in public health preparedness. Despite a challenging Q2, the company raised its full-year revenue forecast and is focusing on improving operational efficiency and reducing debt. Emergent's involvement in global health crises, like mpox, and securing FDA approvals and contracts, positions it as a key player in biodefense. Risks remain due to reliance on government contracts and ongoing restructuring, but recent positive developments support a cautiously optimistic outlook for long-term growth. Read the full article on Seeking AlphaArticle d’analyse • Sep 16
Little Excitement Around Emergent BioSolutions Inc.'s (NYSE:EBS) Revenues As Shares Take 27% Pounding
Emergent BioSolutions Inc. ( NYSE:EBS ) shares have retraced a considerable 27% in the last month, reversing a fair...Seeking Alpha • Aug 18
Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval
Summary Emergent BioSolutions is a key player in public health. Its flagship product, NARCAN, is central to combating the opioid crisis. EBS’s stock rally is likely driven by its smallpox vaccine, ACAM2000, which has potential implications for monkeypox. Potential refinancing and strategic turnaround efforts mitigate the company's financial challenges, including significant debt and cash burn. EBS's MCM portfolio and new government contracts strengthen its position as a trusted biodefense partner. My speculative "buy" rating hinges on EBS’s ability to execute its turnaround, with added potential upside from its possible monkeypox vaccine approval. Read the full article on Seeking AlphaArticle d’analyse • Aug 02
Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 41%
Emergent BioSolutions Inc. ( NYSE:EBS ) shares have continued their recent momentum with a 41% gain in the last month...Seeking Alpha • Jul 15
Emergent BioSolutions: A Much-Needed Mid-Stage Turnaround In Process
Summary Emergent BioSolutions is a commercial stage company focused on developing vaccines and therapeutics to protect against public health threats worldwide. The company experienced a steep decline in stock value due to manufacturing mishaps and scandal during the pandemic, but is now recovering under new CEO Joseph Papa. Despite recent revenue stabilization and positive prospects, investors should approach Emergent with caution. Read the full article on Seeking AlphaAnalyse de la situation financière
Passif à court terme: Les actifs à court terme de EBS ( $637.6M ) dépassent ses passifs à court terme ( $148.7M ).
Passif à long terme: Les actifs à court terme de EBS ( $637.6M ) ne couvrent pas ses passifs à long terme ( $648.6M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de EBS ( 79% ) est considéré comme élevé.
Réduire la dette: Le ratio d'endettement de EBS est passé de 57.2% à 109.7% au cours des 5 dernières années.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: Bien que non rentable EBS dispose d'une piste de trésorerie suffisante pour plus de 3 ans si elle maintient son niveau actuel de flux de trésorerie disponible positif.
Prévisions de trésorerie: EBS n'est pas rentable mais dispose d'une marge de trésorerie suffisante pour plus de 3 ans, même avec un flux de trésorerie disponible positif et en baisse de 7.7 % par an.
Découvrir des entreprises saines
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 04:26 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Emergent BioSolutions Inc. est couverte par 15 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Robert Wasserman | Benchmark Company |
| James Molloy | Brean Capital Historical (Janney Montgomery) |